You can buy or sell Regeneron and other stocks, options, and ETFs commission-free!
Regeneron Pharmaceuticals, Inc. Common Stock, also called Regeneron, is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY. The listed name for REGN is Regeneron Pharmaceuticals, Inc. Common Stock.
Leonard S. Schleifer
Tarrytown, New York
52 Week High
52 Week Low
EU regulator endorses Regeneron antibody cocktail to treat COVID-19
Feb 26 (Reuters) - Europe's medicines regulator said on Friday that an antibody drug combination developed by Regeneron Pharmaceuticals can be used to treat COV
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors
Shares of Regeneron Pharmaceuticals Inc. REGN, -1.18% slipped 1.18% to $453.19 Thursday, on what proved to be an all-around rough trading session for the stock
— per share
Expected May 4, Pre-Market